Research carried out in vitro demonstrated that human tumor-infiltrating lymphocytes exhibited enhanced responsiveness when treated with PBF-509 in conjunction with anti-PD-1 or anti-PD-L1 therapies [175]. Here, CD274 is linked to neoplasm.